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ABSTRACT:
Objective:  To assess the efficacy of Chiropractic spinal
manipulative therapy (SMT) in the treatment of migraine.
Design:  A prospective clinical trial of twelve months
duration.  The trial consisted of 3 stages: two month pre-
treatment, two month treatment, and two months post
treatment.  Comparison of outcomes to the initial baseline
factors was made and also 6 months after the cessation of
the study.
Setting:  Chiropractic Research Centre of Macquarie
University
Participants:  Thirty two volunteers, between the ages of
20 to 65 were recruited through media advertising.  The
diagnosis of migraine was based on a self reported detailed
questionnaire, with minimum of one migraine per month.
Interventions:  Two months of chiropractic SMT at
vertebral fixations determined by the practitioner, through
orthopedic and chiropractic testing.
Main Outcome Measures:  Participants completed diaries
during the entire trial noting the frequency, intensity (visual
analogue score), duration, disability, associated symptoms
and use of medication for each migraine episode.
Results:  The initial 32 participants showed statistically
significant (p < 0.05) improvement in migraine frequency,
VAS, disability, and medication use, when compared to
initial baseline levels.  A further assessment of outcomes
after a six month follow up (based on 24 participants),
continued to show statistically significant improvement
in migraine frequency (p < 0.005), VAS (p < 0.01),
disability (p < 0.05), and medication use (p < 0.01), when
compared to initial baseline levels.
In addition, information was collected regarding any
changes in neck pain following chiropractic SMT.  The
results indicated that 14 participants (58%) reported no
increase in neck pain as a consequence of the two months
of SMT.  Five participants (21%) reported a slight
increase, three participants (13%) reported mild pain, and
two participants (8%) reported moderate pain.
Conclusion:  The results of this study support the
hypothesis that Chiropractic SMT is an effective treatment
for migraine, in some people.  However, a larger controlled
study is required.
Key Indexing Terms (MeSH):  Migraine; chiropractic;
spinal manipulation; prospective trial; neck.
INTRODUCTION
The cervical spine as a cause of headache has been well
described in the literature (1,2).  The Headache
Classification Committee of the International Headaches
Society, has defined cervicogenic headache, in addition
to the other types of headaches, including migraine and
tension type headache (3).
However, the role of spinal conditions (especially the
cervical spine) and their associated treatment for migraine
does not have a well established causal relationship or
clear aetiological pathway (4-7).  In addition, migraine
often has uncertain or overlapping diagnostic criteria thus
making the role of the cervical spine as an aetiological
factor even more uncertain (8,9).
Migraines are a common and debilitating conditions yet
because of this uncertain aetiology, the most appropriate
long term treatment has not been established (9,10).  Most
aetiological models relate to vascular causes of migraine,
where episodes seem to be initiated by a decreased blood
flow to the cerebrum followed by extracranial
vasodilatation during the headache phase (11,12).
However, other aetiological models seem connected with
vascular changes related to neurological causes and
associated serotonergic disturbances (10).  Therefore,
previous treatments have focused on pharmacological
modification of blood flow or serotonin antagonist block
(11).
This paper will evaluate the efficacy of chiropractic spinal
manipulative treatment during a prospective clinical trial
of twelve months duration.
CHIROPRACTIC TREATMENT
Chiropractic SMT is defined as a passive manual
manoeuvre during which the three joint complex is carried
beyond the normal physiological range of movement
without exceeding the boundaries of anatomical integrity
(4).  SMT requires a dynamic force in a specific direction,
usually with a short amplitude to correct a problem of
reduced vertebral motion or positional fault.  Treatment
usually consists of short amplitude, high velocity spinal
manipulative thrusts (diversified technique), on areas of
vertebral fixation determined by a clinical history and
physical examinations
The most commonly used factors to locate vertebral
fixation (denoted vertebral subluxation complex by
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chiropractors) are a clinical history relating to mechanical
pain patterns and medical details to excluded possible non-
mechanical causes (4).  These findings would then be
confirmed by a thorough physical examination, by
assessing which tests/signs (orthopaedic and chiropractic)
were able to reproduce the presenting symptom (7).
Studies in effectiveness and cost-effectiveness of treatment
for back pain have found significant benefit for
chiropractic spinal manipulative therapy (SMT).  These
studies have been detailed in a previous publication by
this author on chiropractic in the workers compensation
system (13).  In addition, numerous studies have identified
improvement in neck pain and headache following
chiropractic SMT (4,7,14-17).
This paper will test an hypothesis that spinal conditions
appear to contribute to the aetiology and morbidity of
migraine.
METHODOLOGY
The study was twelve month prospective clinical trial
which involved 32 subjects who received a two month
course of chiropractic SMT.  Treatment consisted of short
amplitude, high velocity spinal manipulative thrusts
(chiropractic adjustive technique), on areas of vertebral
subluxation determined by the physical examination.
Participants were recruited via the radio and newspapers
in the Sydney region.  Applicants completed a previously
reported questionnaires, and were selected according to
responses in the following symptoms.  The participants
needed to a minimum of 5 of the following IHS indicators:
reaction to pain requiring cessation of activities, the need
to seek a quiet dark area, unilateral pain located parieto-
temporal, pain described as pulsating/throbbing,
associated symptoms of nausea &/or vomiting,
photophobia &/or phonophobia, migraine aggravated by
head or neck movements, and a family history of migraine
(3).
Inclusion was also based on participants experiencing at
least one migraine a month.  Exclusion was based on non-
migraine indicators of a daily migraine or the initiating
factor being trauma.  Participants were also excluded from
the study if there were contra-indications to SMT, such as
meningitis or cerebral aneurysm.  In addition, participants
with temporal arteritis, benign intracranial hypertension
or space occupying lesions were also excluded due to
safety aspects.
Participants completed diaries during the initial six month
trial noting the frequency, VAS, duration, disability,
associated symptoms and use of medication for each
migraine episode.  Participants were instructed how to
complete the diary which contained a table and an
instruction sheet.  Participants had to note the date of the
migraine, an intensity score based on a visual analogue
scale, the hours the migraine lasted and the time before
they could return to normal activities.  In addition,
participants noted associated symptoms using a letter
abbreviation and they noted the type and strength of
medication for each migraine episode.
Patient's blinding was achieved by participants being
informed that they may be randomly assigned to a control
group which would receive a placebo (non effective)
treatment.  Concurrently, the practitioners were "blinded"
to previous treatment results, assignment of control
procedures and other outcome measures.
The first aspect of the trial was conducted over six months,
and consisted of 3 stages: two months pre-treatment, two
months treatment, and two months post treatment.
Participants were contacted by the author a further six
months after the initial trial and asked to complete another
questionnaire regarding their current migraine episodes
for comparison to baseline data.  The follow up
questionnaire sought information on the same outcome
measures, as detailed in the diaries described above.
Comparison was made to initial baseline outcome
measurements of migraine preceding commencement of
SMT, data at the end of the two months post SMT, and to
the six month follow up data.  Statistical analysis involved
comparing the changes of the different outcome
measurements of frequency, VAS, duration, disability, and
medication use throughout the trial.  Statistical tests
employed were a paired t test to test for significant
difference between each group and a one way analysis of
variance (ANOVA) to test for changes for all groups.
RESULTS
Thirty two participants, between the ages of 23 to 60,
joined the study with there being 14 males and 18 females.
Table 1 gives the comparative descriptive statistics for
the group.  The length of time the person had migraines
ranged between 5 to 36 years for the group, with the
average being 18.1 years.  The duration of a typical
migraine episode ranged between 0.75 to 108 hours for
the group, with the average being 23.3 hours.  The
disability (length of time before the person could return
to normal activities) of a typical migraine ranged between
0 to 108 hours for the group, with the average being 25.0
hours.
Table 1.  Comparative Statistics for group prior to
commencement of study
FACTOR DATA
Total Subject n=32
Sex ratio 14M: 18F
Age range 23 to 60 (mean 39.5)
Onset (years) 5 to 36 (mean 23.4)
Frequency (No/ month) 1 to 18 (mean 18.1)
Disability (hours) 0 to 108 (mean 16.3)
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The percentage response for each of the diagnostic criteria
of the IHS guidelines is detailed in table 2 (Table 2).  The
highest responses were for photophobia (91%), nausea
(88%), reaction to pain requiring the person to seek a quiet
dark area (84%), phonophobia (72%), throbbing pain
characteristic (69%), parieto-temporal pain location
(69%), inability to continue normal activities (66%), and
family history (63%).
Table 2.  IHS criteria questionnaire responses for
group prior to commencement of study
The IHS diagnostic criteria with the lowest responses were
aura (31%), migraines aggravated by head or neck
movement (53%), and vomiting (56%).  A moderate
number (44%) of people did not indicate aura as a feature,
however, they described either homonymous visual
changes or parasthesias.  Therefore, the number of people
experiencing migraine with aura (MA) for this group was
twenty four (75%) of a total group of thirty two.
The group showed statistically significant improvement
(p < 0.05) in migraine frequency, VAS, duration and
disability, when compared to initial baseline levels.  The
frequency rates reduced by 46% for the group, severity
reduced by 12%, duration reduced by 20%, disability
reduced by 14% only one participant (3.1 %) reported
that their migraine episodes were worse after the two
months of SMT, but this was not sustained at the two month
post treatment follow up period.  Table 3 demonstrates
variate scores in each of the six diary categories for the
three phases of the trial.
Table 3.  Comparative results for group (n=24) prior to commencement
of study (baseline) and at a 12 month follow up period.
From the initial thirty two participants who entered the
study, four participants failed to complete the entire trial,
one due to alteration in work situation, one due to a
fractured ankle, one due to soreness after SMT, and one
following a perceived worsening of their migraine due to
chiropractic SMT.  In addition, four people failed to return
their six month follow up data, and were excluded from
the assessment.  Therefore the assessment of changes in
migraine at the twelve month period was based on 24
participants.  Table 4 gives the comparative statistics for
this group at the end of the 12 month period.
Table 4.  Changes in outcome measures for group
baseline levels compared to the 12 month follow up.
The average response at twelve months (n=24) showed
statistically significant improvement in migraine frequency
(p < 0.005), VAS (p < 0.01), duration (p < 0.05), and
medication use (p < 0.01), when compared to initial
baseline levels (Figure ????).  The greatest area for
improvement was with the frequency of episodes (60%
reduction), and the associated severity of each migraine
(14% reduction).  In addition, the duration of the migraine
(20% reduction) and the use of medication, reduced
significantly following the SMT intervention (36%
reduction).  Table 3 shows mean variate scores for the
three phases of the trial and statistical significance by
analysis of variance (ANOVA).
Another additional result related to associated neck pain.
Fourteen participants (58%) reported no increase in neck
pain as a consequence of the two months of SMT.  Five
participants (21%) reported slight pain, three participants
(13%) reported mild pain, and two participants (8%)
reported moderate pain.
DISCUSSION
The majority of participants were chronic migraine
sufferers, on average they had experienced migraines for
18.1 years.  However, the results have demonstrated a
significant (p< 0.005) reduction in their migraine episodes
and their associated disability.  The mean number of
migraines per month reduced from 7.6 to 2.6 episodes.
A twelve month study gives the results substantial
significance because a criticism of early studies were that
the length of the trial was too short to allow for the cyclical
nature of migraines (18).  However, the study was limited
in the sample size and the fact that the trial was a pragmatic
study which did not consider what aspects of chiropractic
SNIT had contributed to the improvement in the migraines.
In addition, the study was limited due to the lack of a
control group.  However, it could be argued that
participants acted as their own form of control, due to the
Question Number of
responses (%)
Reaction to pain 27 (84)
Location of pain 22 (69)
Pain character 22 (69)
Inability to continue 21 (66)
Nausea 28 (88)
Vomiting 18 (56)
Aura 10 (31)
Photophobia 29 (91)
Phonophobia 23 (72)
Aggravated by
head/neck movement
17 (53)
Previous diagnosis by specialist 17 (53)
Family history 20 (63)
Visual change/parathesias 14 (44)
Value Freq VAS Dur Dis Med Freq
12M
VASI
2M
Dur
12M
Dis
12M
Med
12M
Mean 6.53 7.88 24.5 24.5 11.8 2.64 6.84 19.7 21.3 7.0
SE 1.46 0.3 7.6 6.7 2.6 0.71 0.3 5.9 6.5 2.6
Median 4 8 9 12 12 1 7 6.5 7 2
Min 0.5 4.5 1.5 1.5 0.5 0.25 4.0 1.5 1.5 0
Max 20 10 120.0 96.0 40 10.0 10.0 72 96 40
Outcome % change p value
Frequency 60% reduction >0.005
VAS 14% reduction >0.01
Duration 20% reduction >0.05
Disability 13% reduction NS
Medication 36% reduction >0.01
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baseline two months data collection, especially given the
fact that this group were chronic migraine sufferers.
A further limitation of this study, as with other studies of
migraine or headaches was that there is substantial overlap
in diagnosis and classification of migraines.  The
questionnaire used in this study proved to have good
reliability, however, there is strong suggestion that many
headache sufferers may have more than one type of
headache (6-9).  An advantage with the design of this study
is that regardless of the exact "diagnosis" of the migraine,
self reported improvement of outcome measures allow
assessment of the validity of the therapy in question (4).
This study appears to confirm that there are a number of
precipitating or aggravating factors involved in migraine
episodes and therefore a single treatment regime may
prove ineffective in the long term (4,5,9,15).
Practitioners need to be aware of the various treatment
strategies and their relative advantages or limitations.
Importantly, many of the associated symptoms suffered
by participants on the trial were reported to be decreased
following the SMT.  The associated symptoms which
decreased following the trial included nausea (41% of
participants felt reduction), photophobia (31 % felt
reduction), vomiting (25% felt reduction), and
phonophobia (25% felt reduction).  Commonly reported
side effects which often increase following pharmaceutical
trials include nausea, vomiting, fatigue, chest pain,
paraesthesia, somnolence, syncope, vertigo and less
commonly atrial fibrillation.  In addition, recent evidence
has identified sumatriptan to be a potential cause of birth
defects and myocardial infarction (19,20).
Whilst not a factor noted by the IHS, stress as either an
aggravating or precipitating factor was cited by 73% of
participants.  In addition, 66% of people reported neck
pain at the time of the migraine, with a further 31 % of
people reporting upper back pain (some people noted both
simultaneously).
Interestingly, five people at the end of the 12 months
followup had no migraines and had decreased need for
medication by 100% following chiropractic SMT.  No
patients reported that their migraines had increased as a
result of the SMT trial.
CONCLUSION
The results of this study support the hypothesis that
Chiropractic SMT is an effective treatment for migraine,
in some people.  However, due to the multifactorial nature
of migraine, and the finding that episodes usually reduce
following any intervention, further larger controlled study
is required.
A prospective randomised controlled trial utilising detuned
EPT (interferential), a sham manipulation group and an
SMT group is nearing conclusion.  It is anticipated this
trial will provide further information of the efficacy of
Chiropractic SMT in the treatment of migraine with aura.
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